Hims & Hers Health Inc.（股票代码：HIMS）今日盘前股价大幅上涨10.66%，引起了市场的广泛关注。
消息面上，股价的强劲表现主要受到两大利好因素推动。首先，美国食品药品监督管理局（FDA）正式宣布将于7月召开专家会议，以敲定肽类药物全面松绑的细节，这一监管动向被视为对作为平价减肥药供应商的Hims & Hers Health的积极信号。
此外，公司宣布与丹麦制药巨头诺和诺德达成合作，后者将通过Hims平台销售其减肥药物。此项合作意味着Hims平台正式切入当前市场需求旺盛的GLP-1减肥药赛道，有望显著拓宽公司的营收来源并提升其用户规模，进一步增强了投资者对公司未来增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.